Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
暂无分享，去创建一个
[1] R. Califf,et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. , 2000, Circulation.
[2] B E Sobel,et al. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. , 1999, The American journal of cardiology.
[3] C. Bode,et al. Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .
[4] McDonald,et al. High-Dose Abciximab During Coronary Angioplasty in a Patient with Essential Thrombocytosis. , 1998, The Journal of invasive cardiology.
[5] D. Praticò,et al. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. , 1997, The Journal of pharmacology and experimental therapeutics.